Heron Therapeutics
HRTX
174 hedge funds and large institutions have $322M invested in Heron Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 26 closing their positions.
413% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $232K
5% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 55
3.44% less ownership
Funds ownership: 115.92% → 112.48% (-3.4%)
7% less funds holding
Funds holding: 187 → 174 (-13)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
52% less capital invested
Capital invested by funds: $677M → $322M (-$355M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.7M |
| 2 |
Walleye Capital
New York
|
+$3.39M |
| 3 |
JP Morgan Chase
New York
|
+$3.05M |
| 4 |
BlackRock
New York
|
+$2.57M |
| 5 |
Citigroup
New York
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$20.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.92M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.24M |
| 4 |
Goldman Sachs
New York
|
-$4.04M |
| 5 |
Millennium Management
New York
|
-$3.9M |
HRTX Hedge Fund Activity: Q2 2022 in Review
174 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2022, worth a combined $322M — down 52% from $677M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of HRTX and 16 opened new positions — a net loss of 10 holders — while 55 trimmed existing stakes and 58 added.
The largest buyer was State Street, adding an estimated $13.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $20.1M sold.
- 174 institutional investors held Heron Therapeutics (HRTX) as of Q2 2022, down from 187 in Q1 2022.
- Funds reported $322M of Heron Therapeutics stock for Q2 2022, down 52% quarter-over-quarter.
- 16 funds opened new Heron Therapeutics positions in Q2 2022 and 26 closed out, a net change of -10 holders.
- The largest Heron Therapeutics buyer in Q2 2022 was State Street, an estimated $13.7M added.
- The largest Heron Therapeutics seller in Q2 2022 was PFM Health Sciences, an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2022.